Detalles de la búsqueda
1.
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Lancet Oncol;
23(12): 1571-1582, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36370716
2.
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol;
22(10): 1458-1467, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34543613
3.
Feasibility and Predictive Performance of a Triage System for Patients with Cancer During the COVID-19 Pandemic.
Oncologist;
26(4): e694-e703, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33539583
4.
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
Breast Cancer Res Treat;
190(2): 265-275, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34476645
5.
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study.
Future Oncol;
16(27): 2059-2073, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32598185
6.
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Lancet Oncol;
19(2): 249-256, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29326029
7.
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.
Future Oncol;
14(9): 849-859, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29527957
8.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet Oncol;
15(6): 640-7, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24657003
9.
Measures of outcome in metastatic breast cancer: insights from a real-world scenario.
Oncologist;
19(6): 608-15, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24794159
10.
Drug waste minimization as an effective strategy of cost-containment in oncology.
BMC Health Serv Res;
14: 57, 2014 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-24507545
11.
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.
EClinicalMedicine;
70: 102501, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38685923
12.
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
BMC Cancer;
13: 164, 2013 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-23537313
13.
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.
EClinicalMedicine;
59: 101931, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37256095
14.
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.
Clin Cancer Res;
29(24): 5217-5226, 2023 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37888299
15.
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Breast Cancer Res Treat;
132(3): 843-51, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21750964
16.
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy.
Anticancer Drugs;
23(3): 326-34, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22129512
17.
CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature.
Curr Oncol;
29(12): 9630-9639, 2022 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36547170
18.
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer.
NPJ Breast Cancer;
8(1): 1, 2022 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35013314
19.
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study.
Target Oncol;
17(6): 615-625, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36152144
20.
Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?
Front Oncol;
12: 885992, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35747814